Alessio Gaggero
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alessio Gaggero has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Jesús Alberto Afonso Urich
Research Center Pharmaceutical Engineering GmbH, 8010 Graz, Austria
3 shared publications - Amrit Paudel
Research Center Pharmaceutical Engineering GmbH, Graz, Austria
2 shared publications Dalibor Jeremic
Department of Health Studies – Biomedical Science, FH JOANNEUM, Alte Poststrasse 149, 8020 Graz, Austria
2 shared publicationsAnna Fedorko
Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria
1 shared publication- Aygün Doğan
Research Center Pharmaceutical Engineering GmbH (RCPE), Inffeldgasse 13, 8010 Graz, Austria
1 shared publication - Carolin Tetyczka
Research Center Pharmaceutical Engineering GmbH, Inffeldgasse 13, 8010 Graz, Austria
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (2) , 610-622
AQbD-driven UHPLC method for simultaneous quantification of budesonide, glycopyrronium bromide, and salbutamol sulphate: a unified approach for inhalation product and bioanalytical applications
Inhalation therapies often combine budesonide, glycopyrronium bromide, and salbutamol sulphate, necessitating analytical methods capable of their simultaneous quantification.
- 15 December 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (2) , 610-622
Open AccessAQbD-driven UHPLC method for simultaneous quantification of budesonide, glycopyrronium bromide, and salbutamol sulphate: a unified approach for inhalation product and bioanalytical applications
Inhalation therapies often combine budesonide, glycopyrronium bromide, and salbutamol sulphate, necessitating analytical methods capable of their simultaneous quantification.
- 15 May 2025
- Published by Wiley in Journal of Separation Science
- Vol. 48 (5) , e70168
Evaluation of Analytical Quality by Design Approaches on the Development and Optimization of Size Exclusion Chromatography Analytical Procedures for Bovine Serum Albumin
The development of analytical procedures, following the International Council of Harmonisation (ICH) regulatory requirements, is crucial for managing the lifecycle of methodologies. This study applies analytical quality by design (AQbD) principles to optimize size exclusion chromatography (SEC) determination for bovine serum albumin (BSA), chosen as a model drug. Key method variables, including mobile phase buffer concentration, flow rate, and column type, were systematically evaluated using risk assessment and design of experiments (DoE). A consistent and rigorous workflow was applied to prove and ensure the robustness of this methodology. The SEC method was established through a framed analytical target profile (ATP), complying with chromatography parameters like tailing, resolution, capacity, and sensitivity. Those were achieved with a Waters XBridge BEH200A SEC column (200 Å, 3.5 µm, 7.8 mm × 300 mm) at 20°C, using a phosphate buffer saline (PBS) solution at pH 7.4 in isocratic elution with a flow of 0.3 mL/min and UV detection of 280 nm. The method was validated according to ICH Q2 ( R 2 ) and Q14 guidelines. The linear response was demonstrated over concentration ranges of 100 µg/mL and 10 mg/mL ( R 2 = 0.9998), and desirable standards of accuracy and precision were met. Although this work highlights the benefits of AQbD in developing trustworthy analytical methods, SEC constitutes a challenge for applying these principles considering the short lifetime of the column, reproducibility, and sensitivity.
- 15 May 2025
- Published by Wiley in Journal of Separation Science
- Vol. 48 (5) , e70168
Evaluation of Analytical Quality by Design Approaches on the Development and Optimization of Size Exclusion Chromatography Analytical Procedures for Bovine Serum Albumin
The development of analytical procedures, following the International Council of Harmonisation (ICH) regulatory requirements, is crucial for managing the lifecycle of methodologies. This study applies analytical quality by design (AQbD) principles to optimize size exclusion chromatography (SEC) determination for bovine serum albumin (BSA), chosen as a model drug. Key method variables, including mobile phase buffer concentration, flow rate, and column type, were systematically evaluated using risk assessment and design of experiments (DoE). A consistent and rigorous workflow was applied to prove and ensure the robustness of this methodology. The SEC method was established through a framed analytical target profile (ATP), complying with chromatography parameters like tailing, resolution, capacity, and sensitivity. Those were achieved with a Waters XBridge BEH200A SEC column (200 Å, 3.5 µm, 7.8 mm × 300 mm) at 20°C, using a phosphate buffer saline (PBS) solution at pH 7.4 in isocratic elution with a flow of 0.3 mL/min and UV detection of 280 nm. The method was validated according to ICH Q2 ( R 2 ) and Q14 guidelines. The linear response was demonstrated over concentration ranges of 100 µg/mL and 10 mg/mL ( R 2 = 0.9998), and desirable standards of accuracy and precision were met. Although this work highlights the benefits of AQbD in developing trustworthy analytical methods, SEC constitutes a challenge for applying these principles considering the short lifetime of the column, reproducibility, and sensitivity.
- Open Access
AQbD-Based UPLC-ELSD Method for Quantifying Medium Chain Triglycerides in Labrafac™ WL 1349 for Nanoemulsion Applications
In response to recent regulatory guidelines, including ICH (International Council for Harmonisation) Q2 (R2) and Q14, we developed a UPLC-ELSD method to quantify Medium-Chain Triglycerides (MCTs) in Labrafac™ WL 1349 for nanoemulsion applications. This procedure, crafted using Analytical Quality by Design (AQbD) principles, addresses not only the validation of the methodology but also the lifecycle management challenges associated with the analysis of lipid-based excipients. Key parameters such as mobile phase composition, organic modifier, column type, flow rate, diluent, and column temperature were optimized to meet regulatory standards and ensure robustness in MCT quantification. Optimal conditions were achieved with a Waters Acquity HSS T3 (100 × 2.1 mm i.d., 1.8 μm) column at 33 °C, using a mixture of methanol (97.5%) and water (2.5%) containing 0.4% of formic acid at a flow rate of 0.41 mL/min. The method demonstrated an excellent fit on a cubic modelization for MCTs over a broad range of concentrations. Forced degradation studies, including hydrolytic (acidic and basic), oxidative, and thermal stress, confirmed the method’s suitability for possible stability scenarios. This validated UPLC method was successfully applied to quantitative analyses of bulk and formulation prototype samples containing MCTs. This AQbD-driven method enhances not only knowledge but also regulatory-compliant and cost-effective excipient control.
Open AccessAQbD-Based UPLC-ELSD Method for Quantifying Medium Chain Triglycerides in Labrafac™ WL 1349 for Nanoemulsion Applications
In response to recent regulatory guidelines, including ICH (International Council for Harmonisation) Q2 (R2) and Q14, we developed a UPLC-ELSD method to quantify Medium-Chain Triglycerides (MCTs) in Labrafac™ WL 1349 for nanoemulsion applications. This procedure, crafted using Analytical Quality by Design (AQbD) principles, addresses not only the validation of the methodology but also the lifecycle management challenges associated with the analysis of lipid-based excipients. Key parameters such as mobile phase composition, organic modifier, column type, flow rate, diluent, and column temperature were optimized to meet regulatory standards and ensure robustness in MCT quantification. Optimal conditions were achieved with a Waters Acquity HSS T3 (100 × 2.1 mm i.d., 1.8 μm) column at 33 °C, using a mixture of methanol (97.5%) and water (2.5%) containing 0.4% of formic acid at a flow rate of 0.41 mL/min. The method demonstrated an excellent fit on a cubic modelization for MCTs over a broad range of concentrations. Forced degradation studies, including hydrolytic (acidic and basic), oxidative, and thermal stress, confirmed the method’s suitability for possible stability scenarios. This validated UPLC method was successfully applied to quantitative analyses of bulk and formulation prototype samples containing MCTs. This AQbD-driven method enhances not only knowledge but also regulatory-compliant and cost-effective excipient control.
- Open Access
- 28 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1290
Comparing Low-Dose Carvedilol Continuous Manufacturing by Solid and Liquid Feeding in Self-Emulsifying Delivery Systems via Hot Melt EXtrusion (SEDEX)
Background/Objectives: This study compared two pilot scale continuous manufacturing methods of solid self-emulsifying drug delivery systems (SEDDSs) via hot melt extrusion (HME). Methods: A model poorly water-soluble drug carvedilol in low dose (0.5–1.0% w/w) was processed in HME either in a conventional powder form or pre-dissolved in the liquid SEDDS. Results: HME yielded a processable final product with up to 20% w/w SEDDS. Addition of carvedilol powder resulted in a non-homogeneous drug distribution in the extrudates, whereas a homogeneous drug distribution was observed in pre-dissolved carvedilol. SEDDSs were shown to have a plasticizing effect, reducing the HME process torque up to 50%. Compatibility between excipients and carvedilol in the studied ratios after HME was confirmed via DSC and WAXS, demonstrating their amorphous form. Solid SEDDSs with Kollidon® VA64 self-emulsified in aqueous medium within 15 min with mean droplet sizes 150–200 nm and were independent of the medium temperature, whereas reconstitution of Soluplus® took over 60 min and mean droplet size increased 2-fold from 70 nm to 150 nm after temperature increased from 25 °C to 37 °C, indicating emulsion phase inversion at cloud point. Conclusions: In conclusion, using Kollidon® VA64 and pre-dissolved carvedilol in SEDDS has shown to yield a stabile HME process with a homogenous carvedilol content in the extrudate.
- 28 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (10) , 1290
Open AccessComparing Low-Dose Carvedilol Continuous Manufacturing by Solid and Liquid Feeding in Self-Emulsifying Delivery Systems via Hot Melt EXtrusion (SEDEX)
Background/Objectives: This study compared two pilot scale continuous manufacturing methods of solid self-emulsifying drug delivery systems (SEDDSs) via hot melt extrusion (HME). Methods: A model poorly water-soluble drug carvedilol in low dose (0.5–1.0% w/w) was processed in HME either in a conventional powder form or pre-dissolved in the liquid SEDDS. Results: HME yielded a processable final product with up to 20% w/w SEDDS. Addition of carvedilol powder resulted in a non-homogeneous drug distribution in the extrudates, whereas a homogeneous drug distribution was observed in pre-dissolved carvedilol. SEDDSs were shown to have a plasticizing effect, reducing the HME process torque up to 50%. Compatibility between excipients and carvedilol in the studied ratios after HME was confirmed via DSC and WAXS, demonstrating their amorphous form. Solid SEDDSs with Kollidon® VA64 self-emulsified in aqueous medium within 15 min with mean droplet sizes 150–200 nm and were independent of the medium temperature, whereas reconstitution of Soluplus® took over 60 min and mean droplet size increased 2-fold from 70 nm to 150 nm after temperature increased from 25 °C to 37 °C, indicating emulsion phase inversion at cloud point. Conclusions: In conclusion, using Kollidon® VA64 and pre-dissolved carvedilol in SEDDS has shown to yield a stabile HME process with a homogenous carvedilol content in the extrudate.